When is CPRX's latest earnings report released?
The most recent financial report for Catalyst pharmaceuticals, inc. (CPRX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CPRX's short-term business performance and financial health. For the latest updates on CPRX's earnings releases, visit this page regularly.
Where does CPRX fall in the P/E River chart?
According to historical valuation range analysis, Catalyst pharmaceuticals, inc. (CPRX)'s current price-to-earnings (P/E) ratio is 14.17, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of CPRX?
According to the latest financial report, Catalyst pharmaceuticals, inc. (CPRX) reported an Operating Profit of 61.85M with an Operating Margin of 40.52% this period, representing a decline of 1.59% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is CPRX's revenue growth?
In the latest financial report, Catalyst pharmaceuticals, inc. (CPRX) announced revenue of 152.61M, with a Year-Over-Year growth rate of 7.61%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does CPRX have?
At the end of the period, Catalyst pharmaceuticals, inc. (CPRX) held Total Cash and Cash Equivalents of 709.17M, accounting for 0.64 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does CPRX go with three margins increasing?
In the latest report, Catalyst pharmaceuticals, inc. (CPRX) achieved the “three margins increasing” benchmark, with a gross margin of 82.9%%, operating margin of 40.52%%, and net margin of 34.5%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CPRX's profit trajectory and future growth potential.
Is CPRX's EPS continuing to grow?
According to the past four quarterly reports, Catalyst pharmaceuticals, inc. (CPRX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.43. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CPRX?
Catalyst pharmaceuticals, inc. (CPRX)'s Free Cash Flow (FCF) for the period is 44.86M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 36.63% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of CPRX?
The latest valuation data shows Catalyst pharmaceuticals, inc. (CPRX) has a Price-To-Earnings (PE) ratio of 14.17 and a Price/Earnings-To-Growth (PEG) ratio of -5.82. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
